391 G (Carbidopa and levodopa extended release 50 mg / 200 mg)
Pill imprint 391 G has been identified as Carbidopa and levodopa extended release 50 mg / 200 mg.
Carbidopa/levodopa is used in the treatment of parkinson's disease; restless legs syndrome; neuroleptic malignant syndrome; gtp-ch deficiency and belongs to the drug class dopaminergic antiparkinsonism agents. Risk cannot be ruled out during pregnancy. Carbidopa/levodopa 50 mg / 200 mg is not a controlled substance under the Controlled Substance Act (CSA).
- Imprint:
- 391 G
- Strength:
- 50 mg / 200 mg
- Color:
- Purple
- Shape:
- Elliptical / Oval
- Availability:
- Prescription only
- Drug Class:
- Dopaminergic antiparkinsonism agents
- Pregnancy Category:
- C - Risk cannot be ruled out
- CSA Schedule:
- Not a controlled drug
- Manufacturer:
- Global Pharmaceuticals
- National Drug Code (NDC):
- 00115-3911
- Inactive Ingredients:
- hydroxypropyl cellulose
magnesium stearate
FD&C Blue No. 2
FD&C Red No. 40
More about carbidopa/levodopa
Consumer resources
- Carbidopa and levodopa
- Carbidopa and levodopa extended-release capsules
- Carbidopa and levodopa orally disintegrating tablets
- Carbidopa and levodopa suspension
- Carbidopa and levodopa sustained-release tablets
- More (6) »
- Other brands: Sinemet, Rytary, Sinemet CR, Parcopa, More (1) »
Professional resources
Related treatment guides
Disclaimer:
Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 2016 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.
